News headlines about Agenus (NASDAQ:AGEN) have trended positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Agenus earned a news impact score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.9934074119042 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Accern’s scoring:

Agenus (NASDAQ:AGEN) traded up 1.71% on Friday, hitting $3.57. 483,682 shares of the stock were exchanged. Agenus has a 52-week low of $3.20 and a 52-week high of $7.49. The stock’s 50 day moving average price is $4.25 and its 200 day moving average price is $3.90. The firm’s market cap is $355.97 million.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.04. The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The business’s revenue for the quarter was down 36.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.33) earnings per share. Equities research analysts forecast that Agenus will post ($1.13) earnings per share for the current year.

AGEN has been the topic of a number of research analyst reports. Maxim Group restated a “buy” rating and issued a $7.00 price target on shares of Agenus in a report on Sunday, April 23rd. HC Wainwright set a $5.00 price target on shares of Agenus and gave the stock a “hold” rating in a report on Saturday, May 6th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Wednesday, July 5th. ValuEngine cut shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Finally, BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $5.88.

ILLEGAL ACTIVITY NOTICE: “Agenus (AGEN) Receives News Sentiment Score of 0.26” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Insider Buying and Selling by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with's FREE daily email newsletter.